Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture

Song, Yanling, Zhu, Zhi, An, Yuan, Zhang, Weiting, Zhang, Huimin, Liu, Dan, Yu, Chundong, Duan, Wei and Yang, Chaoyong James 2013, Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture, Analytical chemistry, vol. 85, no. 8, pp. 4141-4149.

Attached Files
Name Description MIMEType Size Downloads

Title Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture
Author(s) Song, Yanling
Zhu, Zhi
An, Yuan
Zhang, Weiting
Zhang, Huimin
Liu, Dan
Yu, Chundong
Duan, Wei
Yang, Chaoyong James
Journal name Analytical chemistry
Volume number 85
Issue number 8
Start page 4141
End page 4149
Total pages 9
Publisher American Chemical Society
Place of publication Washington DC
Publication date 2013-04
ISSN 0003-2700
1520-6882
Keyword(s) breast cancer cells
circulating tumor cells
epithelial cell adhesion molecules
Summary Epithelial cell adhesion molecule (EpCAM) is overexpressed in most solid cancers and is an ideal antigen for clinical applications in cancer diagnosis, prognosis, imaging, and therapy. Currently, most of the EpCAM-based diagnostic, prognostic, and therapeutic strategies rely on the anti-EpCAM antibody. However, the use of EpCAM antibody is restricted due to its large size and instability. In this study, we have successfully identified DNA aptamers that selectively bind human recombinant EpCAM protein. The aptamers can specifically recognize a number of live human cancer cells derived from breast, colorectal, and gastric cancers that express EpCAM but not bind to EpCAM-negative cells. Among the aptamer sequences identified, a hairpin-structured sequence SYL3 was optimized in length, resulting in aptamer sequence SYL3C. The Kd values of the SYL3C aptamer against breast cancer cell line MDA-MB-231 and gastric cancer cell line Kato III were found to be 38±9 and 67±8 nM, respectively, which are better than that of the full-length SYL3 aptamer. Flow cytometry analysis results indicated that the SYL3C aptamer was able to recognize target cancer cells from mixed cells in cell media. When used to capture cancer cells, up to 63% cancer cell capture efficiency was achieved with about 80% purity. With the advantages of small size, easy synthesis, good stability, high binding affinity, and selectivity, the DNA aptamers reported here against cancer biomarker EpCAM will facilitate the development of novel targeted cancer therapy, cancer cell imaging, and circulating tumor cell detection.
Language eng
Field of Research 111504 Pharmaceutical Sciences
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2013, American Chemical Society
Persistent URL http://hdl.handle.net/10536/DRO/DU:30059532

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in TR Web of Science
Scopus Citation Count Cited 11 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 26 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Thu, 16 Jan 2014, 11:11:27 EST by Jane Moschetti

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.